Physician profile
Sera Satoi
NPI 1679189195
$954.79
in general payments reported to CMS, 2019-2025
12 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $110 · 2024: $643 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $880 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $879.80 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $189.35 | 2024-2025 | Stelara, Tremfya |
| Abbvie INC. | $171.59 | 2023-2025 | Rinvoq, Skyrizi |
| Astrazeneca Pharmaceuticals LP | $125.56 | 2024 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $122.41 | 2023-2024 | Entyvio |
| Lilly USA, LLC | $99.87 | 2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.18 | 2024-2025 | Xifaxan, Plenvu |
| Mallinckrodt Hospital Products INC. | $48.17 | 2024-2025 | Terlivaz |
| Gilead Sciences, INC. | $29.21 | 2024 | Livdelzi |
| Ipsen Biopharmaceuticals, INC | $21.00 | 2024 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $19.82 | 2023 | |
| Pfizer INC. | $19.39 | 2024 | |
| Merck Sharp & Dohme LLC | $19.24 | 2023 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sera Satoi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.